DE3302949C2 - - Google Patents

Info

Publication number
DE3302949C2
DE3302949C2 DE3302949A DE3302949A DE3302949C2 DE 3302949 C2 DE3302949 C2 DE 3302949C2 DE 3302949 A DE3302949 A DE 3302949A DE 3302949 A DE3302949 A DE 3302949A DE 3302949 C2 DE3302949 C2 DE 3302949C2
Authority
DE
Germany
Prior art keywords
administration
nasal
dihydroergotamine
caffeine
theophylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3302949A
Other languages
German (de)
English (en)
Other versions
DE3302949A1 (de
Inventor
Jean-Rene Kiechel
Danielle Rueil-Malmaison Fr Plas
Francoise Elancourt Fr Acezat-Mispelter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Patent GmbH filed Critical Sandoz Patent GmbH
Publication of DE3302949A1 publication Critical patent/DE3302949A1/de
Application granted granted Critical
Publication of DE3302949C2 publication Critical patent/DE3302949C2/de
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE19833302949 1982-02-01 1983-01-29 Nasal verabreichbare pharmazeutische zusammensetzungen Granted DE3302949A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8202781 1982-02-01

Publications (2)

Publication Number Publication Date
DE3302949A1 DE3302949A1 (de) 1983-08-11
DE3302949C2 true DE3302949C2 (US20100268047A1-20101021-C00004.png) 1992-05-21

Family

ID=10528017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19833302949 Granted DE3302949A1 (de) 1982-02-01 1983-01-29 Nasal verabreichbare pharmazeutische zusammensetzungen

Country Status (27)

Country Link
JP (1) JPS58134017A (US20100268047A1-20101021-C00004.png)
AT (1) AT385656B (US20100268047A1-20101021-C00004.png)
AU (1) AU565613B2 (US20100268047A1-20101021-C00004.png)
BE (1) BE895750A (US20100268047A1-20101021-C00004.png)
CA (1) CA1197783A (US20100268047A1-20101021-C00004.png)
CH (1) CH653555A5 (US20100268047A1-20101021-C00004.png)
DE (1) DE3302949A1 (US20100268047A1-20101021-C00004.png)
DK (1) DK164771C (US20100268047A1-20101021-C00004.png)
ES (1) ES519450A0 (US20100268047A1-20101021-C00004.png)
FI (1) FI81258C (US20100268047A1-20101021-C00004.png)
FR (1) FR2539994B1 (US20100268047A1-20101021-C00004.png)
GR (1) GR81320B (US20100268047A1-20101021-C00004.png)
HK (1) HK59989A (US20100268047A1-20101021-C00004.png)
HU (1) HU191512B (US20100268047A1-20101021-C00004.png)
IE (1) IE54532B1 (US20100268047A1-20101021-C00004.png)
IL (1) IL67822A (US20100268047A1-20101021-C00004.png)
IT (1) IT1197558B (US20100268047A1-20101021-C00004.png)
KE (1) KE3888A (US20100268047A1-20101021-C00004.png)
LU (1) LU84613A1 (US20100268047A1-20101021-C00004.png)
MY (1) MY8700766A (US20100268047A1-20101021-C00004.png)
NL (1) NL192325C (US20100268047A1-20101021-C00004.png)
NZ (1) NZ203117A (US20100268047A1-20101021-C00004.png)
PH (1) PH22198A (US20100268047A1-20101021-C00004.png)
PT (1) PT76166B (US20100268047A1-20101021-C00004.png)
SE (1) SE454402B (US20100268047A1-20101021-C00004.png)
SG (1) SG34389G (US20100268047A1-20101021-C00004.png)
ZA (1) ZA83673B (US20100268047A1-20101021-C00004.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
GB0910375D0 (en) * 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US20190209463A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) * 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB1202885A (en) * 1966-12-22 1970-08-19 Sandoz Ltd Pharmaceutical compositions comprising alkaloids
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
FR2387035A1 (fr) * 1977-04-12 1978-11-10 Cassenne Lab Sa Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux
DE2831728C2 (de) * 1978-07-19 1982-12-23 Krewel-Werke Gmbh, 5208 Eitorf Arzneimittel zur Behandlung von Kopfschmerzen

Also Published As

Publication number Publication date
FR2539994B1 (fr) 1986-10-10
PT76166B (en) 1986-02-04
PT76166A (en) 1983-02-01
HK59989A (en) 1989-08-04
IL67822A0 (en) 1983-06-15
ZA83673B (en) 1984-09-26
HU191512B (en) 1987-02-27
FR2539994A1 (fr) 1984-08-03
KE3888A (en) 1989-09-01
DK38183D0 (da) 1983-01-31
FI81258C (fi) 1990-10-10
FI830245A0 (fi) 1983-01-25
ES8502865A1 (es) 1985-02-01
IE830187L (en) 1983-08-01
DK164771B (da) 1992-08-17
JPS58134017A (ja) 1983-08-10
CH653555A5 (de) 1986-01-15
BE895750A (fr) 1983-08-01
DK164771C (da) 1992-12-28
JPH0253406B2 (US20100268047A1-20101021-C00004.png) 1990-11-16
IL67822A (en) 1988-02-29
DK38183A (da) 1983-08-02
SE454402B (sv) 1988-05-02
SE8300495D0 (sv) 1983-01-31
IE54532B1 (en) 1989-11-08
AU1085083A (en) 1983-08-11
NL192325C (nl) 1997-06-04
PH22198A (en) 1988-06-28
MY8700766A (en) 1987-12-31
CA1197783A (en) 1985-12-10
IT1197558B (it) 1988-12-06
FI81258B (fi) 1990-06-29
AT385656B (de) 1988-05-10
GR81320B (US20100268047A1-20101021-C00004.png) 1984-12-11
SE8300495L (sv) 1983-08-02
IT8347646A0 (it) 1983-02-01
ES519450A0 (es) 1985-02-01
FI830245L (fi) 1983-08-02
NZ203117A (en) 1986-12-05
NL8300325A (nl) 1983-09-01
SG34389G (en) 1989-09-22
LU84613A1 (fr) 1983-09-08
ATA30383A (de) 1987-10-15
DE3302949A1 (de) 1983-08-11
AU565613B2 (en) 1987-09-24
NL192325B (nl) 1997-02-03

Similar Documents

Publication Publication Date Title
EP1283036B1 (de) Multidosis-Trockenpulverinhalator mit Pulverreservoir
EP1121112B1 (de) Lagerfähiges wirkstoffkonzentrat mit formoterol
EP0316633B1 (de) Azelastin enthaltende Arzneimittel zur Anwendung in der Nase und/oder am Auge
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE3815221C2 (de) Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE60034476T2 (de) Topische nasenbehandlung mit desloratadin und mometason furoat
DE3335086C2 (US20100268047A1-20101021-C00004.png)
DE1492015A1 (de) Verbesserte Verabreichungsform pharmazeutischer Praeparate
DE2851543A1 (de) Inhalationspraeparat
DE19921693A1 (de) Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE60002885T2 (de) Wässrige formulierung zur nasalen verabreichung
DE1792410B2 (de) Arzneimittelzubereitung zur intravenösen Injektion
EP0214620B1 (de) Transdermale Applikationsform von Diltiazem
EP1663141B1 (de) Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
DE69229688T4 (de) Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten
DE3527587A1 (de) Nasale zubereitungen
DE3302949C2 (US20100268047A1-20101021-C00004.png)
EP0277462A1 (de) Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin.
EP0529499A1 (de) Pharmazeutische Zusammensetzungen enthaltend Bradykinin-Antagonisten zur lokalen Anwendung an Nase und Auge
DE10014007A1 (de) Neue Darreichungsformen für DSIP
AT402895B (de) Verfahren zur herstellung einer flüssigen pharmazeutischenzusammensetzung für die nasale verabreichung eines calcitonins als nasaler spray
EP0465841A2 (de) Schnellwirksame Inhalationsarzneiformen von Diuretika
DE112019000683T5 (de) Intranasale epinephrin-formulierungen und verfahren zur behandlung von erkrankungen
DE19502566A1 (de) N-Acetyl-Cystein-haltige pharmazeutische Zusammensetzungen
DE19536916A1 (de) Inhalative Applikation von 2-Amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol, insbesondere seines (-)-Enantiomeren, sowie deren pharmakologisch verträgliche Säureadditionssalze

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: A61K 31/52

D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8328 Change in the person/name/address of the agent

Free format text: SPOTT WEINMILLER & PARTNER, 80336 MUENCHEN